Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 5/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252440 | 0.80 | NCF1 (0.42) | NCF1ACHEHRH3HTR4GNAI3 | |
| SCHEMBL5255432 | 0.80 | SMN1; SMN2 (0.40) | ACHEHRH3 | |
| SCHEMBL133081 | 0.79 | — | — | |
| SCHEMBL30435158 | 0.79 | SLC1A3 (0.34) | — | |
| SCHEMBL26502000 | 0.79 | CHRNB2 (0.41) | MAOAMAOBHRH3HDAC1HDAC2 | |
| SCHEMBL1820774 | 0.78 | HTR4 (0.36) | NCF1HTR4GNAI3GNAO1GNAI1 | |
| SCHEMBL5252486 | 0.77 | CYP4F2 (0.39) | HDAC3HDAC1HDAC2 | |
| SCHEMBL27431706 | 0.76 | NCF1 (0.42) | NCF1ACHEMAOAMAOBHRH3 | |
| SCHEMBL5255635 | 0.76 | — | — | |
| SCHEMBL457302 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | NCF1 1719/4885ACHE 2157/4885MAOA 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.